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OBJECTIVE: The aim of the pilot retrospective study 
was to implement PATS in the process of evaluation of
pharmacotherapy of hospitalized diabetics. In 3-months
cycles, collected data on pharmacotherapy were com-
pared with clinical guidelines and hospital formulary.
METHODS: In 148 hospitalized diabetics with the most
frequent diagnosis E107 (diabetes mellitus with multi-
organ complications) were collected data on pharma-
cotherapy in 3-months cycles. Data collected from
patients’ charts included clinical diagnosis, all adminis-
tered drugs and their dosage forms, single and daily-
prescribed doses. Those data were entered via custom-
made software module in the form of drug-chart into the
clinical information system PATS (Patient Analysis and
Tracking System). The basic data were programmatically
processed to a standard PATS registry for further analy-
sis. The data on drugs prescription were retrieved using
the ATC classiﬁcation. These data were compared both
with the clinical guidelines used in the department and
hospital formulary. RESULTS: According to the 3 digital
ATC codes, the prescribed drugs were from 53 different
groups. The most frequently prescribed drugs were drugs
used in diabetes (313 drugs including insulins), the fol-
lowing groups are ordered according to the frequency 
of use: antibiotics (123), diuretics (92), antithrombotic
agents (89), and agents acting on the renin-angiotensin
system (73). The further analysis has shown that there is
a great variability in pharmacotherapy in patients with
the same diagnosis, e.g. 7 different ACE inhibitors were
administered to the patients. CONCLUSION: PATS is a
very useful and ﬂexible tool in assessment of rational
pharmacotherapy of hospitalized patients.
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OBJECTIVE: A longitudinal, retrospective study was 
performed to investigate the cost of illness attributed 
to primary open angle glaucoma (POAG). METHODS:
Patients were identiﬁed using ICD-9 code 365.11. Three-
year data associated with POAG were collected from
patient charts in two clinics by a reviewer using a data
collection form. A second reviewer veriﬁed data entry,
including visual ﬁeld (VF) mean deviation (MD), physi-
cian’s assessment (PA), and resource utilization (physician
visits, procedures, and medications). VF was classiﬁed
mild (MD < 5dB), moderate (5 ≥ MD < 12dB), or severe
(MD ≥ 12dB); and PA as stable, uncontrolled, or delayed
stable (uncontrolled for 12 months, then stable).
Resources were costed in Canadian dollars from the 
Ministry of Health perspective using standard lists. Costs
were summed for each patient, then contrasted between
groups using ANOVA with Scheffe’s post-hoc test 
(a = 0.05). RESULTS: Of 411 patient charts extracted,
235 provided useable data (mean follow-up 4 years); 35
excluded patients had ocular comorbidities, 141 had
insufﬁcient follow-up data (<3 years). Mean costs (SD)
for VF groups mild (n = 80), moderate (n = 81), and
severe (n = 74) were $376 ($279), $493 ($314), and $586
($251), respectively. Analysis by PA for stable (n = 115),
uncontrolled (n = 62), and delayed stable (n = 58) yielded
costs of $437 ($269), $506 ($320), and $547 ($306),
respectively. In the VF analysis, differences were signiﬁ-
cant (p < 0.05) between all groups for the ﬁrst half of 
the follow-up period and between mild and severe for 
the entire follow-up period. For PA, the mean cost of the
stable group was the lowest, without however signiﬁcant
differences. DISCUSSION and CONCLUSIONS: The
cost of treating POAG increases with severity, especially
when applying VF categories. Hence, severity in terms of
VF score may give an indication of the magnitude of the
expected total cost. Further examination of the relation-
ship between VF and other clinical parameters, such as
intra-ocular pressure, is warranted.
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OBJECTIVES: To describe the patterns and the eco-
nomics of glaucoma treatment. METHODS: Ophthal-
mologists selected at random had to include 4 consecutive
patients older than 18 seen in consultation during a week,
2 with glaucoma and 2 with ocular hypertension (OH).
Socio-demographics, general and eye comorbidities, glau-
coma risk factors, clinical data, and medical item con-
sumption over the previous 5 years were collected. The
economic perspective was society’s. Predictive medical
factors of costs were identiﬁed using a stepwise regres-
sion. RESULTS: 84 ophthalmologists included 337
patients who were 60% female with a mean age of 62;
34.1% had OH and 35.9% were still receiving ﬁrst line
treatment. Glaucoma patients were older and no differ-
ence was found on confounding factors. Patients with
